Abiopharma

🔍 NORRIS ELWOOD G (Executive)

Company: WRAP TECHNOLOGIES, INC. (WRAP)

Report Date: 2026-02-02

Detailed Transactions and Holdings:

• Sold 31,991 shares of Common Stock at $2.0768 per share (Direct)
  Date: 2026-02-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,268,033.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 20,000 shares of Common Stock at $2.201 per share (Direct)
  Date: 2026-02-03 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,236,042.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 75,000 shares of Common Stock at $1.8743 per share (Direct)
  Date: 2026-02-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,216,042.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 35,000 shares of Common Stock at $1.8164 per share (Direct)
  Date: 2026-02-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,141,042.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 27,104 shares of Common Stock at $1.8186 per share (Direct)
  Date: 2026-02-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,113,938.00 | transaction_form_type: 4 | Footnotes: F5

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.04 to $2.10 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) of this Form 4. The amount reflected has been rounded to 2 decimal points.
• F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1,985 to $2.08 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) of this Form 4. The amount reflected has been rounded to 3 decimal points.
• F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.85 to $1.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) of this Form 4. The amount reflected has been rounded to 2 decimal points.
• F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.795 to $1.825, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) of this Form 4. The amount reflected has been rounded to 3 decimal points.
• F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.80 to $1.232, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) of this Form 4. The amount reflected has been rounded to 3 decimal points.
• REMARKS: As a result of the foregoing sales, Mr. Norris no longer beneficially owns 10% or more of the Common Stock. Subsequent sales by Mr. Norris have not been listed. Mr. Norris has not made any purchases of the Common Stock since February 10, 2026.